INFI Infinity Pharmaceuticals Inc

Price (delayed)

$0.7347

Market cap

$65.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.52

Enterprise value

$13.15M

Infinity Pharmaceuticals, Inc. ('Infinity' or the 'Company'), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of ...

Highlights
INFI's debt is down by 41% year-on-year and by 15% since the previous quarter
Infinity Pharmaceuticals's EPS has increased by 19% YoY
The company's equity has shrunk by 81% YoY and by 54% QoQ
Infinity Pharmaceuticals's quick ratio has shrunk by 56% YoY and by 17% QoQ

Key stats

What are the main financial stats of INFI
Market
Shares outstanding
89.16M
Market cap
$65.5M
Enterprise value
$13.15M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.56
Price to sales (P/S)
32.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.44
Earnings
Revenue
$2.04M
EBIT
-$45.89M
EBITDA
-$45.41M
Free cash flow
-$40.71M
Per share
EPS
-$0.52
Free cash flow per share
-$0.46
Book value per share
$0.11
Revenue per share
$0.02
TBVPS
$0.81
Balance sheet
Total assets
$72.58M
Total liabilities
$62.6M
Debt
$777,000
Equity
$9.98M
Working capital
$56.71M
Liquidity
Debt to equity
0.08
Current ratio
5.23
Quick ratio
5.01
Net debt/EBITDA
1.15
Margins
EBITDA margin
-2,222.6%
Gross margin
100%
Net margin
-2,255%
Operating margin
-2,247.1%
Efficiency
Return on assets
-52%
Return on equity
-175.1%
Return on invested capital
N/A
Return on capital employed
-77.5%
Return on sales
-2,246.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INFI stock price

How has the Infinity Pharmaceuticals stock price performed over time
Intraday
-11.89%
1 week
0.71%
1 month
28.71%
1 year
-75.83%
YTD
-67.35%
QTD
-35.55%

Financial performance

How have Infinity Pharmaceuticals's revenue and profit performed over time
Revenue
$2.04M
Gross profit
$2.04M
Operating income
-$45.91M
Net income
-$46.07M
Gross margin
100%
Net margin
-2,255%
The company's gross profit rose by 16% YoY and by 10% QoQ
The revenue has grown by 16% year-on-year and by 10% since the previous quarter
The operating income has contracted by 16% YoY
The net income has declined by 12% year-on-year

Growth

What is Infinity Pharmaceuticals's growth rate over time

Valuation

What is Infinity Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.56
P/S
32.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.44
Infinity Pharmaceuticals's EPS has increased by 19% YoY
The company's equity has shrunk by 81% YoY and by 54% QoQ
The stock's price to book (P/B) is 49% more than its 5-year quarterly average of 4.4 but 25% less than its last 4 quarters average of 8.8
INFI's P/S is 72% below its last 4 quarters average of 114.2 and 33% below its 5-year quarterly average of 47.8
The revenue has grown by 16% year-on-year and by 10% since the previous quarter

Efficiency

How efficient is Infinity Pharmaceuticals business performance
The ROE has soared by 96% year-on-year but it has declined by 42% since the previous quarter
INFI's return on assets is up by 22% year-on-year but it is down by 13% since the previous quarter
Infinity Pharmaceuticals's return on sales has increased by 7% QoQ

Dividends

What is INFI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INFI.

Financial health

How did Infinity Pharmaceuticals financials performed over time
Infinity Pharmaceuticals's total assets is 16% more than its total liabilities
Infinity Pharmaceuticals's quick ratio has shrunk by 56% YoY and by 17% QoQ
INFI's current ratio has dropped by 55% year-on-year and by 16% since the previous quarter
INFI's debt is 92% smaller than its equity
The debt to equity has soared by 167% YoY and by 100% from the previous quarter
The company's equity has shrunk by 81% YoY and by 54% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.